NantHealth, Inc.
NHIQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -3.15 | 0.59 | 0.03 |
| FCF Yield | -137.77% | -27.20% | -6.29% | -11.75% |
| EV / EBITDA | -7.62 | -11.95 | -10.51 | -11.98 |
| Quality | ||||
| ROIC | -40.36% | -23.74% | -14.86% | -14.57% |
| Gross Margin | 56.96% | 55.61% | 60.06% | 59.96% |
| Cash Conversion Ratio | 0.48 | 0.47 | 0.30 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.89% | -13.25% | -6.48% | 3.45% |
| Free Cash Flow Growth | -18.20% | -45.48% | -68.67% | 66.76% |
| Safety | ||||
| Net Debt / EBITDA | -6.89 | -7.81 | -3.74 | -7.80 |
| Interest Coverage | -3.64 | -2.82 | -1.37 | -1.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 48.15 |
| Cash Conversion Cycle | -89.92 | -5.26 | -42.50 | 65.38 |